In Vitro Activities of Ceftazidime-Avibactam and Comparator Antimicrobial Agents Tested against ESBL Producing Urinary E. coli Isolates

Yıl 2019, , 112 - 115, 15.09.2019

Estelle Caine Ozlem Koyuncu Ozyurt Gozde Ongut Kubra Kasaroglu Emre Yıldız Dilara Ogunc Filiz Gunseren Dilek Colak Ozge Turhan Betil Ozhak

https://doi.org/10.5799/jmid.614195

Öz

Objectives: Urinary tract infections (UTIs) remain one of the most
common infections for antibiotic prescription. Increased resistance to
antibiotics currently used to treat these infections may lead to significant
problems. Extended spectrum beta-lactamase (ESBL) production in organisms
causing UTIs are often responsible for the increase in resistance. The aim of
this study was to investigate the in vitro antimicrobial susceptibility of ESBL
producing community acquired urinary E.
coli isolates to Ceftazidime/Avibactam (CAZ/AVI) and other antimicrobial
agents using disk diffusion method.

Methods:
Between 2016 and 2017, a total of 100 ESBL producing E. coli urine isolates were collected from outpatients who had no
history of hospitalization in the last three months in Akdeniz University
Hospital. All isolates were tested for in vitro susceptibility to the CAZ/AVI
and other antimicrobial agents using disk diffusion method. Results: No CAZ/AVI and carbapenem
resistance were observed. Resistance rates to other antimicrobial agents were
as follows: ampicillin 100%, amoxicillin/clavulanate 85%, cefotaxime 98%,
ceftazidime 89%, cefepime 82%, gentamicin 41%, ciprofloxacin 65%, levofloxacin
39%, fosfomycin 3%, nitrofurantoin 2%, trimethoprim/sulfamethoxazole 72% and
Piperacillin/Tazobactam 41%.

Conclusions: Our results showed that ceftazidime / avibactam,
carbapenems, nitrofurantoin and fosfomycin may be among the first line
treatment options in the empirical therapy. In selected patients, CAZ/AVI could
be an option for the treatment of UTI caused by ESBL producing E.coli which may reduce the use of
carbapenems. J Microbiol Infect Dis
2019; 9(2):112-115.

Anahtar Kelimeler

Ceftazidime-avibactam, ESBL, Urinary tract infections, in vitro

Kaynakça

• 1. Picozzi SC, Casellato S, Rossini M, et al. Extended-spectrum beta-lactamase positive Escherichia coli causing complicated upper urinary tract infection: Urologist should act in time. Urol Ann 2014; 6(2):107-12. 2. Gupta K, Hooton TM, Naber KG, et al. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis. 2011;52(5):e103-20. 3. Keepers TR, Gomez M, Celeri C, Krause KM, Biek D, Critchley I. Fosfomycin and Comparator Activity Against Select Enterobacteriaceae, Pseudomonas, and Enterococcus Urinary Tract Infection Isolates from the United States in 2012. Infect Dis Ther. 2017; 6(2):233-243. 4. Schwaber MJ, Navon-Venezia S, Kaye KS, Ben-Ami R, Schwartz D, Carmeli Y. Clinical and economic I mpact of bacteremia with extended- spectrum-beta-lactamase-producing Enterobacteriaceae. Antimicrob Agents Chemother. 2006; 50(4):1257-1262. 5. Popejoy MW, Paterson DL, Cloutier D, et al. Efficacy of ceftolozane/tazobactam against urinary tract and intra-abdominal infections caused by ESBL-producing Escherichia coli and Klebsiella pneumoniae: a pooled analysis of Phase 3 clinical trials. J Antimicrob Chemother 2017; 72(1):268-272. 6. D'Angelo RG, Johnson JK, Bork JT, Heil EL. Treatment options for extended-spectrum beta-lactamase (ESBL) and AmpC-producing bacteria. Expert Opin Pharmacother. 2016; 17(7):953-967. 7. The European Committee on Antimicrobial Susceptibility Testing. EUCAST guideline for the detection of resistance mechanisms and specific resistances of clinical and/or epidemiological importance. Version 2.0, 2017. http://www.eucast.org. 8. The European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters. Version 7.1, 2017. http://www.eucast.org. 9. Forster CS, Courter J, Jackson EC, Mortensen JE, Haslam DB. Frequency of Multidrug-Resistant Organisms Cultured From Urine of Children Undergoing Clean Intermittent Catheterization. J Pediatric Infect Dis Soc 2017 ;6(4):332-338. 10. Shaikh S, Fatima J, Shakil S, Rizvi SM, Kamal MA. Antibiotic resistance and extended spectrum beta-lactamases: Types, epidemiology and treatment. Saudi J Biol Sci. 2015;22(1):90-101. 11. Mendes RE, Castanheira M, Woosley LN, Stone GG, Bradford PA, Flamm RK. Molecular β-lactamase characterization of gram-negative pathogens recovered from patients enrolled in the ceftazidime-avibactam phase 3 trials (RECAPTURE 1 and 2) for complicated urinary tract infections: Efficacies analysed against susceptible and resistant subsets. Int J Antimicrob Agent 2018; S0924-8579(18)30103-1. 12. Karlowsky JA, Biedenbach DJ, Kazmierczak KM, Stone GG, Sahm DF. Activity of Ceftazidime-Avibactam against Extended-Spectrum- and AmpC β-Lactamase-Producing Enterobacteriaceae Collected in the INFORM Global Surveillance Study from 2012 to 2014. Antimicrob Agents Chemother 2016; 60(5):2849-2857. 13. Karlowsky JA, Kazmierczak KM, Bouchillon SK, de Jonge BLM, Stone GG, Sahm DF. In Vitro Activity of Ceftazidime-Avibactam against Clinical Isolates of Enterobacteriaceae and Pseudomonas aeruginosa Collected in Asia-Pacific Countries: Results from the INFORM Global Surveillance Program, 2012 to 2015. Antimicrob Agents Chemother. 2018; 62(7). pii: e02569- e02517. 14. Aktaş Z, Kayacan C, Oncul O. In vitro activity of avibactam (NXL104) in combination with β-lactams against Gram-negative bacteria, including OXA-48 β-lactamase-producing Klebsiella pneumoniae. Int J Antimicrob Agents. 2012; 39(1):86-89. 15. Yin D, Wu S, Yang Y, et al. China Antimicrobial Surveillance Network (CHINET) Study Group. Results from the China Antimicrobial Surveillance Network (CHINET) in 2017 of the In VitroActivities of Ceftazidime-Avibactam and Ceftolozane-Tazobactam against Clinical Isolates of Enterobacteriaceae and Pseudomonas aeruginosa. Antimicrob Agents Chemother 2019; 63(4):e02431-e02418. 16. European Centre for Disease Prevention and Control. Emergence of resistance to ceftazidime-avibactam in carbapenem-resistant Enterobacteriaceae – 12 June 2018. Stockholm, ECDC; 2018. 17. Gupta K, Hooton TM, Naber KG, et al. Infectious Diseases Society of America; European Society for Microbiology and Infectious Diseases. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis. 2011; 52(5):e103-e120. 18. Sanchez GV, Baird AM, Karlowsky JA, Master RN, Bordon JM. Nitrofurantoin retains antimicrobial activity against multidrug-resistant urinary Escherichia coli from US outpatients. J Antimicrob Chemother. 2014; 69(12):3259-3262. 19. .http://www.tmc-online.org/pdf/Pinar_Ciragil.pdf